Despite the lack of randomized controlled trials (RCTs) showing the effect of lipid-lowering treatment on reducing cardiovascular events in FH, pharmacologic therapies (e.g., statins, ezetimibe and anti-PCSK9 monoclonal antibodies) remain highly recommended for CVD risk management in this population. This evidence concerns the gene PCSK9 and familial hyperaldosteronism.